Lung Bioengineering purchased an XVIVO Perfusion System (XPS™) with STEEN Solution Perfusate from XVIVO Perfusion AB (STO: XVIVO) for use in its Jacksonville Ex Vivo Lung Perfusion (EVLP) center. XVIVO Perfusion will continue to provide training and supplies for use of their machines by transplant hospitals to re-evaluate donated lungs that have initially been deemed unsuitable for transplant. Lung Bioengineering and XVIVO Perfusion will also continue to cooperate and collaborate in promoting the use of centralized XPS EVLP services that could increase the supply of transplantable lungs to address needless patient deaths on the transplant waitlist.
On April 26, 2019 XVIVO received Premarket approval (PMA) from the FDA for XPS with STEEN Solution Perfusate for sale on the American market. The XPS with STEEN Solution Perfusate was the first medical device that was approved for EVLP of initially unacceptable donated lungs.
“We are very pleased that the collaboration agreement is extended to Lung Bioengineering´s new Jacksonville facility. United Therapeutics’ impressive history of developing and delivering innovative and effective therapies for severe lung diseases makes them the ideal partner for XVIVO Perfusion in our quest to prevent mortality due to organ shortages,” said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion.
August 23, 2019
Magnus Nilsson
Gothenburg
XVIVO Perfusion AB (publ)